{"title": "Posible encefalopat\u00eda t\u00f3xica no alcoh\u00f3lica por vacuna Covid en paciente con hepatopat\u00eda", "author": "Jos\u00e9 Mar\u00eda Gonz\u00e1lez San Jos\u00e9", "url": null, "hostname": null, "description": "Since the beginning of the inoculations of experimental gene therapies called \"Covid vaccines\", the presence of multisystemic symptoms of different types and severities has been observed. We report the case of encephalopathy in a patient awaiting liver transplantation, at the time not affiliated with an acute or chronic, alcoholic or viral digestive process, and possibly caused by a brain inflammatory process mediated by the toxic capacity of nanoparticle excipients. lipids present in Covid vaccines (mRNA type) that have the property of crossing the blood-brain barrier (BBB). The patient was previously informed of the risk of encephalopathy by the Primary Care nursing staff. Nursing has a fundamental role in prevention and tracking adverse effects in the short, medium and long term.", "sitename": "Evidentia", "date": "2023-02-06", "cleaned_text": "Posible encefalopat\u00eda t\u00f3xica no alcoh\u00f3lica por vacuna Covid en paciente con hepatopat\u00eda Possible non-alcoholic toxic encephalopathy due to Covid vaccine in a patient with liver disease Resumen Abstract Bibliograf\u00eda 1), 5-9. https://doi.org/10.1007/s40265-018-1018-z 2. Medline Plus. National Library of Medicine (NIH - NLM) U.S. Department of Health and Human Services. ADAM Health Solutions. 1997-2022. Encefalopat\u00eda Hep\u00e1tica. (Sitio Web). https://medlineplus.gov/spanish/ency/article/000302.htm. 3. Bosch B, van der Zee R, de Haan C, & Rottier P. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. Journal of Virology 2003; 77(16). https://doi.org/10.1128/jvi.77.16.8801-8811.2003 4. Gonz\u00e1lez San Jos\u00e9, Jos\u00e9 Mar\u00eda. Necrosis de pie por isquemia arterial aguda tras vacuna Covid. Evidentia. 2022; 29: e13916. http://ciberindex.com/c/ev/e13916 5. Romero de San P\u00edo, E., Romero de San P\u00edo, M., & Gonz\u00e1lez S\u00e1nchez, S. Derecho al honor, al prestigio y a la salvaguarda de la dignidad profesional en enfermer\u00eda. Revista Ene De Enfermer\u00eda. 2016; 10(1). http://ene-enfermeria.org/ojs/index.php/ENE/article/view/607 6. Organizaci\u00f3n Mundial de la Salud. Centro Internacional de monitorizaci\u00f3n de medicamentos. Centro de monitorizaci\u00f3n de Uppsala. Datos de Efectos Adversos para \"Covid-19 vaccine\". (VIGIACCESS) https://www.vigiaccess.org/ 7. Perez, Jean Claude, Moret-Chalmin, L. Towards the emergence a new disease: Twenty-six cases of CJD a a COVID-19 \"vaccine\" Jab. 2021. Disponible en: https://canadahealthalliance.org/wp-content/uploads/2022/06/V2CJDPerezMoretMontagnierRIP2022REFERENCEARTICLE.pdf 8. National Vaccine Information Center. Creutzfeldt-Jakob disease. MedAlert.org (Sitio Web). 2022. https://medalerts.org/vaersdb/findfield.php?TABLE=ON&GROUP1=AGE&EVENTS=ON&SYMPTOMS=Creutzfeldt-Jakob+disease+%2810011384%29&VAX=COVID19 9. Lazarus R, Klompas M, & Berstein S. Electronic for Public Health-Vaccine Adverse Event Reporting System (ESP: VAERS). U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality (AHRQ). 2010 (Rockvi-lle 147-175. https://doi.org/10.1007/978-94-007-4899-6_7 13. Zhang, L., Richards, A., Barrasa, M., Hughes, S., Young, R., & Jaenisch, R. Reverse-transcribed SARS-CoV-2 RNA can inte-grate into the genome of cultured 2021; 118(21). Expresi\u00f3n del Receptor ACE2 (Target de SARS-CoV-2) en Tejidos Humanos y Cavidad Oral. Posibles Rutas de Infecci\u00f3n en \u00d3rganos Orales. International journal of odontostomatology 2020; 14(4). http://dx.doi.org/10.4067/S0718-381X2020000400501 15. Sun S.-H, Yang G, Wang Y-X, Huang X-Y et al. A Mouse Model of J-C, Turner A, et al. 2020; 126(10), 1456-1474. https://doi.org/10.1161/CIRCRESAHA.120.317015 X-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in Delivery. Disponible en https://www.echelon-inc.com/lipid-nanoparticles-for-rna-delivery/ 19. National Center for Biotechnology Information (NCBI). National Institute of Health (NIH). PUBCHEM., SM-102. de Na-tional Center for Biotechnology Information (NCBI): Disponible en https://www.ncbi.nlm.nih.gov/pcsubstance/?term=sm-102 20. National Center for Biotechnology Information (NCBI). National Institute of Health (NIH). PUBCHEM., ALC-0315. de Na-tional Center for Biotechnology Information (NCBI): Disponible en https://www.ncbi.nlm.nih.gov/pcsubstance/?term=alc-0315 21. National Center for Biotechnology Information (NCBI). National Institute of Health (NIH). PUBCHEM., ALC-0159. de Na-tional Center for Biotechnology Information (NCBI): Disponible Y.-J., G., & Lamb, H. Polyethylene glycol-liposomal doxorubicin: a review of its use in the C., & Kang, Y. Formulation and delivery of itraconazole to the brain using a nanolipid carrier system. Int Nanomedicine 2014; 9, https://doi.org/10.2147/IJN.S57565 25. Radice, A., Clin Molina, P., Baeza Ochoa de Oc\u00e1riz, M., & Zubeldia Ortu\u00f1o, J. Safety of New mRNA (Pag 2009. 29. Paredes Rizo M\u00aa Luisa. Sensibilidad Qu\u00edmica M\u00faltiple: an\u00e1lisis de un caso registrado en un Hospital de referencia. Med. segur. trab. Resumen visto - 825 veces - PDF descargado - 40 veces "}